Drug sponsors balked at increasing user fee funding for the Patient-Focused Drug Development and Complex Innovative trial Design programs, questioning the additional staff proposed to maintain and expand them.
Members of the prescription drug user fee reauthorization negotiating teams are finalizing language for the commitment letter that would extend the program another five years. (Also see "PDUFA Renewal Negotiations Nearly Complete, With CBER Slated For Major Resource Increase" - Pink Sheet, 19 February, 2021
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?